drugset / Trial / NCT00526838
Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety and tolerability of the multi-targeted protein kinase inhibitor XL228 (active against IGF1R, Src, FGFR, and BCR-Abl) administered as a once- or twice-weekly 1-hour intravenous infusion in subjects with advanced malignancies.
Timeline
- Start
- 2007-09
- Primary completion
- 2010-12
- Completion
- 2010-12
Outcome
Outcome not reported
Stopped (Business): “Sponsor decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | XL228 | Small molecule | — | Intravenous |